Testing a cholesterol drug to improve heart blood flow on scans
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 50 years old (men) or 55 years old (women)
- Your LDL (bad cholesterol) is at least 70 mg/dL
- You have stable coronary artery disease with evidence of limited heart blood flow on prior testing (scan, angiogram/CT, or high coronary calcium score)
- If you take a statin, your dose has been the same for at least 3 months
- You have not had a heart attack or stroke
- You cannot currently use a PCSK-9 inhibitor (this drug) and must not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
This study tests whether evolocumab, a monthly injection, can shrink the fatty buildup (plaque) in your heart arteries. It is for people who have early signs of heart disease or diabetes but have not had a heart attack or stroke yet.
This study tests an educational program to help people understand and lower their LDL ('bad') cholesterol after a heart-related event. It aims to improve awareness and encourage the use of cholesterol-lowering treatments.
This study looks at how well two cholesterol-lowering medicines, evolocumab and alirocumab, work in people with high cholesterol or heart disease. It reviews medical records from patients at a specific hospital to see how these medicines affect cholesterol levels.
This trial tests whether a drug that lowers cholesterol (a PCSK9 inhibitor) can help patients preparing for aneurysm surgery. It will examine how the drug affects the aneurysm tissue during surgery, which may guide future treatment.
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
Hear when a new Stable Coronary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.